TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer

Background: Resistance or even hyper-progression to immune checkpoint inhibitors (ICIs) manifesting as accelerated disease progression or death has impeded the clinical use of ICIs. The transforming growth factor beta (TGFβ) receptor pathway has been identified in contributing to immune dysfunction,...

Full description

Bibliographic Details
Main Authors: Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li, Zhijie Wang
Format: Article
Language:English
Published: SAGE Publishing 2021-08-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211038477

Internet

https://doi.org/10.1177/17588359211038477

Similar Items